Use of GELSECTAN® in Patients with Irritable Bowel Syndrome (IBS): an Italian Experience

Patient Prefer Adherence. 2021 Aug 13:15:1763-1774. doi: 10.2147/PPA.S318859. eCollection 2021.

Abstract

Irritable bowel syndrome is a chronic functional gastrointestinal disorder characterized by recurrent chronic abdominal pain and impaired bowel habits, which affects daily activity and work productivity, and is associated with a significant healthcare economic burden as well as an impaired quality of life and psycho-affective profile. Management of patients is a great challenge for physicians; at the present, the therapeutic strategy aimed to treat the different symptoms, and no medical therapy is proven to modify the natural history of the disease. GELSECTAN® (xyloglucan, pea protein and tannins, xylo-oligosaccharides) is a medical device with both protective and prebiotic actions on the intestinal mucosa, able to restore intestinal permeability and to improve gastrointestinal symptoms, controlling diarrhoea, abdominal pain and bloating in adult patients with irritable bowel syndrome. We report and discuss four cases of different patients with irritable bowel syndrome successfully managed with Gelsectan in the real clinical practice. Literature data, as well as these case reports, show that this device is effective and safe in improving symptoms and bowel habits associated to irritable bowel syndrome; its efficacy and safety were confirmed for the long-term use too. Agents with film-forming protective properties, such as Gelsectan, represent a new alternative therapeutic option for the management of patients with irritable bowel syndrome.

Keywords: GELSECTAN®; irritable bowel syndrome; tannins; xylo-oligosaccharides; xyloglucan.

Publication types

  • Case Reports

Grants and funding

Norgine Italia has provided support for the publication fees of case reports of patients with IBS-D treated with GELSECTAN®. Norgine Italia did not condition the writing of the article or provide grant to the authors.